The case for & against
Bull & Bear analysis
Bullish
Celldex Therapeutics, Inc. (NASDAQ: CLDX) is an emerging biotechnology company focused on developing innovative immunotherapies for cancer and other serious diseases. With a robust pipeline including the new bispecific CDX-622, Celldex is positioned in the rapidly evolving immunology sector, addressing significant unmet medical needs with its unique therapeutic approaches.
Bull says
- ↑Phase 1 CDX-622 delivered dose-dependent, durable serum tryptase reductions.
- ↑Two Phase 3 barzolvolimab trial readouts in late 2026 could spark stock gains.
- ↑Strong institutional backing with high 13F ownership suggests future outperformance.
- ↑Positive price momentum post-trial news reflects growing investor confidence.
- ↑Analysts have begun modestly raising estimates after trial success.
- ↑Pipeline focus positions Celldex in the high-growth immunotherapy market.
Bear says
- ↓Profitability remains deeply negative, highlighting ongoing net losses.
- ↓High leverage increases debt service pressure and liquidity risk.
- ↓Negative P/E of –9.16 underscores lack of confidence in earnings.
- ↓Elevated short interest reflects persistent investor skepticism and volatility.
- ↓Weak growth metrics suggest challenges in scaling revenues.
- ↓Competition from large pharma could limit Celldex’s market share.
Investment themes with CLDX
Biotech↓ -1.57%
Genetic and drug innovations driving medical breakthroughs
APLS · RVMD · SMMT
Earnings Call · Q4 2021 · Mgmt. Guidance
Updated 07-22-2026neutral
Transcript signals
Bull points
- In July 2021, we reported positive data from our lead candidate, CDX0159, a unique mast cell depleting antibody. The Phase I and chronic-inducible urticaria results were presented during a late-breaking poster discussion session at the IACI Annual Congress and demonstrated that patients experienced a 95% complete response rate and an overall response rate of 100% after only a single dose of 0159.
- Today we are pleased to report positive results from our Phase 1 subcutaneous formulation of CDX0159 in healthy volunteers. Subcutaneous administration of CDX0159 eliminated the mild infusion reactions observed in some individuals dosed with the IV formulation, and we were very pleased that none of the volunteers had injection site reactions as sometimes observed with subcutaneous formulations.
- The successful development of the CDXL159 subcutaneous formulation is a key step forward in the development of this program as it offers a convenient administration route for patients and physicians.
Bear points
- In further support of our Phase II urticaria program, we recently completed the in-life dosing portion of our six-month chronic toxicology study. This study was a standard chronic toxicology study designed to support longer-term dosing in our Phase II studies. We conducted the study in sexually mature non-human primates to allow us to also capture data on potential impact on reproductive organs.
- The only clinically adverse finding reported was on spermatogenesis, an expected and well-understood effect of KIT inhibition.
- the one single clinically adverse finding reported from our six-month chronic tox study was an impact on spermatogenesis, which we fully expected because this has been well described and studied as an effect of kit inhibition.
Read full transcript analysis ›